US 9220676
Injectable in-situ crosslinked hydrogel and methods of making and using thereof
granted A61KA61K9/0019A61K9/0024
Quick answer
US patent 9220676 (Injectable in-situ crosslinked hydrogel and methods of making and using thereof) held by BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
- Grant date
- Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K9/0019, A61K9/0024, A61P, A61P31/00